Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
INTS 
Intensity Therapeutics, Inc. Common stock (INTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: INTS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.92
1 Year Target Price $2.92
| 1 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.26% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 28.23M USD | Price to earnings Ratio - | 1Y Target Price 2.92 |
Price to earnings Ratio - | 1Y Target Price 2.92 | ||
Volume (30-day avg) 5 | Beta 4.24 | 52 Weeks Range 0.19 - 3.17 | Updated Date 12/13/2025 |
52 Weeks Range 0.19 - 3.17 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.55 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -101.66% | Return on Equity (TTM) -234.7% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21281533 | Price to Sales(TTM) - |
Enterprise Value 21281533 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.72 | Shares Outstanding 60064965 | Shares Floating 54806277 |
Shares Outstanding 60064965 | Shares Floating 54806277 | ||
Percent Insiders 10.38 | Percent Institutions 7.02 |
About Intensity Therapeutics, Inc. Common stock
Exchange NASDAQ | Headquaters Shelton, CT, United States | ||
IPO Launch date 2023-06-30 | Founder, President, CEO & Chairman of the Board Mr. Lewis H. Bender M.A., M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | |
Full time employees 5 | |||
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.